+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Recipharm AB (RECI B) - Financial and Strategic SWOT Analysis Review

  • ID: 4284780
  • SWOT Analysis
  • 53 pages
  • GlobalData
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • Boehringer Ingelheim GmbH
  • F. Hoffmann-La Roche Ltd
  • Fareva SA
  • Iconovo AB
  • MORE
Recipharm AB (RECI B) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

Critical Information Included
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Recipharm AB (Recipharm) is a contract development and manufacturing organization (CDMO) that offers manufacturing, and development and technology services. The company's manufacturing segment provides contract manufacturing of pharmaceuticals such as semi-solids, and oral liquids, solid dose, sterile products, besides clinical trial materials including APIs and other drugs. Recipharm’s development and technology segment offers raw material supply, formulation development and development of validated analytical methods, among others. The company operates in the UK, Germany, Spain, Italy, Sweden, France, and others. Recipharm is headquartered in Stockholm, Sweden.

Recipharm AB Key Recent Developments

Feb 28, 2019 Recipharm achieves new ISO 45001 certification to support sustainability efforts
Feb 21, 2019 Recipharm publishes its report for the fourth quarter and full year 2018
Feb 14, 2019 Recipharm announces all its facilities are ready for EU serialisation
Feb 12, 2019 Recipharm names new Director of Business Management

Key Benefits

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Boehringer Ingelheim GmbH
  • F. Hoffmann-La Roche Ltd
  • Fareva SA
  • Iconovo AB
  • MORE
Section 1 - About the Company
  • Recipharm AB - Key Facts
  • Recipharm AB - Key Employees
  • Recipharm AB - Key Employee Biographies
  • Recipharm AB - Major Products and Services
  • Recipharm AB - History
  • Recipharm AB - Company Statement
  • Recipharm AB - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 – Company Analysis
  • Company Overview
  • Recipharm AB - Business Description
  • Business Segment: D&T
  • Overview
  • Performance
  • Business Segment: MFG-SL
  • Overview
  • Performance
  • Business Segment: MFG-SO
  • Overview
  • Performance
  • Geographical Segment: France
  • Performance
  • Geographical Segment: Germany
  • Performance
  • Geographical Segment: India
  • Performance
  • Geographical Segment: Italy
  • Performance
  • Geographical Segment: Other
  • Performance
  • Geographical Segment: Portugal
  • Performance
  • Geographical Segment: Spain
  • Performance
  • Geographical Segment: Sweden
  • Performance
  • Recipharm AB - Corporate Strategy
  • Recipharm AB - SWOT Analysis
  • SWOT Analysis - Overview
  • Recipharm AB - Strengths
  • Recipharm AB - Weaknesses
  • Recipharm AB - Opportunities
  • Recipharm AB - Threats
  • Recipharm AB - Key Competitors
Section 3 – Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
  • Recipharm AB, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
  • Recipharm AB, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
  • Recipharm AB, Recent Deals Summary
Section 5 – Company’s Recent Developments
  • Feb 28, 2019: Recipharm achieves new ISO 45001 certification to support sustainability efforts
  • Feb 21, 2019: Recipharm publishes its report for the fourth quarter and full year 2018
  • Feb 14, 2019: Recipharm announces all its facilities are ready for EU serialisation
  • Feb 12, 2019: Recipharm names new Director of Business Management
  • Dec 19, 2018: Recipharm to potentially end operations in Ashton-under-Lyne facility
  • Nov 08, 2018: Recipharm publishes its interim report January - September 2018
  • Oct 25, 2018: Manufacturing licence restriction at Recipharm, Ashton-u-Lyne, UK facility
  • Oct 19, 2018: Recipharm continues manufacturing operations in Hoganas, Sweden
  • Oct 09, 2018: Recipharm releases first serialised products to Europe
  • Oct 03, 2018: Recipharm names Tobias Hagglov as Chief Financial Officer
Section 6 – Appendix
  • Methodology
  • Ratio Definitions
  • About the Author
  • Contact Us
  • Disclaimer
List of Tables
  • Recipharm AB, Key Facts
  • Recipharm AB, Key Employees
  • Recipharm AB, Key Employee Biographies
  • Recipharm AB, Major Products and Services
  • Recipharm AB, History
  • Recipharm AB, Other Locations
  • Recipharm AB, Subsidiaries
  • Recipharm AB, Key Competitors
  • Recipharm AB, Ratios based on current share price
  • Recipharm AB, Annual Ratios
  • Recipharm AB, Annual Ratios (Cont...1)
  • Recipharm AB, Annual Ratios (Cont...2)
  • Recipharm AB, Interim Ratios
  • Recipharm AB, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
  • Recipharm AB, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
  • Recipharm AB, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Recipharm AB, Performance Chart (2014 - 2018)
  • Recipharm AB, Ratio Charts
  • Recipharm AB, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
  • Recipharm AB, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Vetter Pharma-Fertigung GmbH & Co KG
  • Iconovo AB
  • Fareva SA
  • Famar Health Care Services
  • F. Hoffmann-La Roche Ltd
  • Corden Pharma International GmbH
  • Boehringer Ingelheim GmbH
Note: Product cover images may vary from those shown
Adroll
adroll